title: Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of maintenance treatment with oral cyclophosphamide (Cy) and bevacizumab (Bev) in patients with recurrent ovarian cancer.
  
  
  METHODS
  Induction treatment consisted of cisplatin, epirubicin, Cy and Bev every 3 weeks, for a maximum of six cycles. Maintenance treatment consisted of oral Cy 50 mg, days 1-14 and Bev 15 mg/kg, every 3 weeks until disease progression occurred.
  
  
  RESULTS
  In total, 39 patients were enrolled: after induction chemotherapy, the objective response was 74.3%. The median progression-free survival was 13.3 months, and the median overall survival was 33.2 months. Toxicity during maintenance treatment was mild.
  
  
  CONCLUSIONS
  Maintenance with Cy and Bev may achieve encouraging results in terms of progression-free survival and overall survival in recurrent ovarian cancer patients.
authors: Medical Oncology Unit, Department of Medicine, Surgery & Neurosciences, University of Siena, Viale Bracci, 53100 Siena, Italy.
authors: Roberto
authors: R
authors: Petrioli
authors: Medical Oncology Unit, Department of Medicine, Surgery & Neurosciences, University of Siena, Viale Bracci, 53100 Siena, Italy.
authors: Giandomenico
authors: G
authors: Roviello
authors: Pharmacology Unit, Department of Medicine, University of Siena, Siena, Italy.
authors: Anna Ida
authors: AI
authors: Fiaschi
authors: Medical Oncology Unit, Department of Medicine, Surgery & Neurosciences, University of Siena, Viale Bracci, 53100 Siena, Italy.
authors: Letizia
authors: L
authors: Laera
authors: Medical Oncology Unit, Department of Medicine, Surgery & Neurosciences, University of Siena, Viale Bracci, 53100 Siena, Italy.
authors: Salvatora Tindara
authors: ST
authors: Miano
authors: Unit of General & Minimally Invasive Surgery, Surgery & Neurosciences, University of Siena, Italy.
authors: Daniele
authors: D
authors: Marrelli
authors: Unit of Surgical Oncology, Surgery & Neurosciences, University of Siena, Italy.
authors: Franco
authors: F
authors: Roviello
authors: Medical Oncology Unit, Policlinico Umberto I Hospital, University of Rome, Rome, Italy.
authors: Vincenzo
authors: V
authors: Bianco
authors: Medical Oncology Unit, Policlinico Umberto I Hospital, University of Rome, Rome, Italy.
authors: Edoardo
authors: E
authors: Francini
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage; D000077216:Carcinoma, Ovarian Epithelial; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D060046:Maintenance Chemotherapy; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D019233:Retreatment; D016896:Treatment Outcome
chemical_list: D000068258:Bevacizumab; D003520:Cyclophosphamide
keywords: bevacizumab; carboplatin; cisplatin; epirubicin; lyposomal doxorubicin; ovarian cancer